t(3;21)(q26;q22) in myeloid leukemia: An aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy

Cancer

Volumn 106, Issue 8, 2006, Pages 1730-1738

  Cameron Yin, C ^a   Cortes, Jorge ^a   Barkoh, Bedia ^a   Hayes, Kimberly ^a   Kantarjian, Hagop ^a   Jones, Dan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

5 fluorouracil; Chronic myeloid leukemia; Etoposide; Fludarabine; Hydroxyurea; Therapy related leukemia

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANAGRELIDE; BUSULFAN; CD34 ANTIGEN; CD7 ANTIGEN; CD9 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; HYDROXYUREA; IDARUBICIN; IFOSFAMIDE; INTERFERON; MESNA; METHOTREXATE; MITOXANTRONE; NILOTINIB; PREDNISONE; THALIDOMIDE; TIPIFARNIB; TOPOTECAN; TRANSCRIPTION FACTOR RUNX1; TROXACITABINE; UNINDEXED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLAST TRANSFORMATION; BONE MARROW TRANSPLANTATION; CELL MATURATION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; DNA SEQUENCE; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; IMMUNOPHENOTYPING; KARYOTYPE; LEUKEMIA REMISSION; MALE; MEGAKARYOCYTE; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOID LEUKEMIA; MYELOPROLIFERATIVE DISORDER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRISOMY 8;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BONE MARROW; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 3; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA-BINDING PROTEINS; FEMALE; HUMANS; HYDROXYUREA; LEUKEMIA, MYELOID; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENES; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC;

EID: 33646075159     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21797     Document Type: Article

References (28)

1. Gilliland DG. Molecular genetics of human leukemias: new insights into therapy. Semin Hematol. 2002;39:6-11.
2. Downing JR. The core-binding factor leukemias: lessons learned from murine models. Curr Opin Genet Dev. 2003;13:48-54.
3. Speck NA, Gilliland DG. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer. 2002;2:502-513.
4. Nucifora G, Begy CR, Erickson P, Drabkin HA, Rowley JD. The 3;21 translocation in myelodysplasia results in a fusion transcript between the AML1 gene and the gene for EAP, a highly conserved protein associated with the Epstein-Barr virus small RNA EBER 1. Proc Natl Acad Sci U S A. 1993;90:7784-7788.
5. Mitani K, Ogawa S, Tanaka T, et al. Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J. 1994;13:504-510.
6. Nucifora G, Begy CR, Kobayashi H, et al. Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3; 21)(q26;q22) translocations. Proc Natl Acad Sci U S A. 1994;91:4004-4008.
7. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
8. Hao S, Sanger W, Onciu M, Lai R, Schlette EJ, Medeiros LJ. Mantle cell lymphoma with 8q24 chromosomal abnormalities: a report of 5 cases with blastoid features. Mod Pathol. 2002;15:1266-1272.
9. Yin CC, Medeiros LJ, Glassman AB, Lin P. t(8;21)(q22;q22) in blast phase of chronic myelogenous leukemia. Am J Clin Pathol. 2004;121:836-842.
10. Zent C, Kim N, Hiebert S, et al. Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties. Curr Top Microbiol Immunol. 1996;211:243-252,
11. Senyuk V, Chakraborty S, Mikhail FM, Zhao R, Chi Y, Nucifora G. The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells. Oncogene. 2002;21:3232-3240,
12. Senyuk V, Sinha KK, Chakraborty S, Buonamici S, Nucifora G. P/CAF and GCN5 acetylate the AML1/MDS1/EVI1 fusion oncoprotein. Biochem Biophys Res Commun. 2003;307:980-986.
13. Helbling D, Mueller BU, Timchenko NA, et al. The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of calreticulin. Proc Natl Acad Sci U S A. 2004;101:13312-13317.
14. Fears S, Mathieu C, Zelezni-Le N, Huang S, Rowley JD, Nucifora G. Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. Proc Natl Acad Sci U S A. 1996;93:1642-1647.
15. Sood R, Talwar-Trikha A, Chakrabarti SR., Nucifora G. MDS1/EVI1 enhances TGF-beta1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1. Leukemia. 1999;13:348-357.
16. Morishita K, Suzukawa K, Taki T, Ihle JN, Yokota J. EVI-1 zinc finger protein works as a transcriptional activator via binding to a consensus sequence of GACAAGATAA-GATAAN1-28 CTCATCTTC. Oncogene. 1995;10:1961-1967.
17. Mitani K. Molecular mechanisms of leukemogenesis by AML1/EVI-1. Oncogene. 2004;23:4263-4269.
18. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164-172.
19. Cortes J, O'Dwyer ME. Clonal evolution in chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004;18:671-684.
20. Cuenco GM, Ren R, Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice. Oncogene. 2004;23:569-579.
21. Andersen MK, Christiansen DH, Pedersen-Bjergaard J. Amplification or duplication of chromosome band 21q22 with multiple copies of the AML1 gene and mutation of the TP53 gene in therapy-related MDS and AML. Leukemia. 2005;19:197-200.
22. Slovak ML, Bedell V, Popplewell L, Arber DA, Schoch C, Slater R. 21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: report from an international workshop. Genes Chromosomes Cancer. 2002;33:379-394.
23. Pedersen-Bjergaard J, Philip P. Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase 11. Blood. 1991;78:1147-1148.
24. Nielsen I, Hasselbalch HC. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am J Hematol. 2003;74:26-31.
25. Bernasconi P, Boni M, Cavigliano PM, et al. Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea. Leukemia. 2002;16:2078-2083.
26. Mitelman F. The cytogenetic scenario of chronic myeloid leukemia. Leak Lymphoma. 1993;11(Suppl 1):11-15.
27. Johansson B, Fioretos T, Garwicz S, Heim S, Mitelman F. t(3;21)(q26;q22) with AML1 rearrangement in a de novo childhood acute monoblastic leukaemia. Br J Haematol. 1996;92:429-431.
28. Morishita K, Parganas E, William CL, et al. Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26. Proc Natl Acad Sci U S A. 1992;89:3937-3941.